Macular DegenerationNCT00058695
Genetic Factors in Age-Related Macular Degeneration
An observational study of Macular Degeneration, run by National Eye Institute (NEI) at 1 site in United States.
Trial summary
This study will examine whether certain polymorphisms (small gene variances) predispose people to develop age-related macular degeneration (AMD). This eye condition affects people over 50 years of age and can cause permanent loss of central vision. Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Macular Degeneration
- How many people
- 477 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Apr 2003to 21 Oct 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- AMD Patients (cases):
- Diagnosis of advanced AMD defined by geographic atrophy and/or choroidal neovascularization with drusen of any size in at least one eye.
- Age 50 years or older.
- If sample previously donated in a different study, the patient has given their permission to use their sample (i.e. marked appropriate selection in the informed consent).
- Control Patients (controls):
- Absence of drusen or no more than 5 drusen less than 63 microns, absence of other diagnostic criteria for AMD.
- Agrees to undergo study examinations.
Who cannot join
- Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD loss such as high myopia, retinal dystrophies, central serous retinopathy, vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases that have been present prior to the age of 50.
- Opacities of the ocular media, limitations of papillary dilation or other problems sufficient to preclude adequate stereo fundus photography. These conditions include occluded pupils due to synechiae, cataracts, vitreous haze and opacities due to ocular diseases.
Trial locations and contacts
1 site in 1 country.
United States1 site
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892
About this study
Official title: Evaluation of Single Nucleotide Polymorphism (SNP) in Patients With and Subjects Without Age-Related Macular Degeneration (AMD)
This study will examine whether certain polymorphisms (small gene variances) predispose people to develop age-related macular degeneration (AMD). This eye condition affects people over 50 years of age and can cause permanent loss of central vision. The study will examine and compare the frequency of polymorphisms in patients with AMD to that of individuals without AMD. This information will help identify genetic risk factors for the AMD and may lead to the development of more effective treatments.
Patients 50 years of age and older with advanced AMD and healthy normal volunteers may be eligible for this study. All participants will provide an eye health history and will have 10 milliliters (2 teaspoons) of blood drawn from an arm vein. The DNA in the blood will be isolated and tested for certain genes that other research indicates are important in aging and age-related diseases. The normal and polymorphic gene sequences will be identified and compared in patients with AMD and control subjects to determine if any of the polymorphisms are related to development of AMD.
Read more
In addition, control subjects will have a routine eye examination, including dilation of the pupils for examination of the back of the eye.
...
Read the detailed description
Age-related macular degeneration (AMD) is the leading cause of irreversible severe central visual loss older than 50 in the world.1 The incidence and progression of all the features of AMD are known to increase significantly with age.2-4 In a recent study, Klein et al. reported that approximately 15.6% of the US population aged 60 years and older in 2005-2008 had signs of AMD.5 In a study in Iceland, the prevalence of early AMD was 12.4% for those aged 66 to 74 years and 36% for those aged 85 years and older.6 Currently in the United States, advanced AMD affects more than 1.75 million people and the number will increase to 2.95 million by the year 2020.7
Epidemiological studies of genome wide association study (GWAS), candidate gene association, and linkage disequilibrium suggest that AMD has a significant genetic component.7-10 Ample evidence supports the hypothesis that variance of genes involved in DNA repair,11-13 oxidative stress14, 15 and inflammation16-20 play a role in aging and age-related diseases. Many studies have documented the association between polymorphisms in complement factors (CF), oxidative stress, apolipoprotein E (ApoE), mitochondria and chaperone proteins genes and AMD.21-23 Single nucleotide polymorphism (SNP) in ApoE, ApoE or C2/BF may protect AMD. On the other hand, SNP in CFH, AMRS2/HTRA-1 or CX3CR1 gene may increase AMD risk.24 In this study, we would like to test whether the variations of biologically plausible genes (or the modifying genes) listed above are differentially distributed in AMD patients and normal populations. To this end, we choose genes that are believed to play a crucial role in the aging process and will analyze the frequency of SNPs specifically within the coding frames of biologically plausible genes responsible for aging and age-related diseases.
Our aim will be to compare the allelic frequencies of candidate genes listed above in cohorts with AMD to the frequency in normal control subjects without AMD. With this study we hope to identify genetic risk factors that could have functional implications for understanding and treating AMD.
- Conditions
- Macular Degeneration
- Keywords
- Macualar Degeneration, AMD, Healthy Volunteer, HV
- Medical subject headings
- Macular Degeneration
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of SNP
Measured: Ongoing
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Apr 2003 (estimated)
- Study start4 Apr 2003
- Study completion21 Oct 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 477 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Eye Institute (NEI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Robert B Nussenblatt, M.D., Principal investigator, National Eye Institute (NEI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00058695
- Sponsor's protocol ID
- 030155
- Other IDs
- 03-EI-0155
- Status last verified
- 21 Oct 2015
- First submitted
- 11 Apr 2003
- Last updated
- 14 Feb 2018
- Results posted
- No
Publications
Tuo J, Ross RJ, Herzlich AA, Shen D, Ding X, Zhou M, Coon SL, Hussein N, Salem N Jr, Chan CC. A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. Am J Pathol. 2009 Aug;175(2):799-807. doi: 10.2353/ajpath.2009.090089. Epub 2009 Jul 16.
PubMed 19608872Ablikim M, Achasov MN, Albayrak O, Ambrose DJ, An FF, An Q, Bai JZ, Baldini Ferroli R, Ban Y, Becker J, Bennett JV, Bertani M, Bian JM, Boger E, Bondarenko O, Boyko I, Braun S, Briere RA, Bytev V, Cai H, Cai X, Cakir O, Calcaterra A, Cao GF, Cetin SA, Chang JF, Chelkov G, Chen G, Chen HS, Chen JC, Chen ML, Chen SJ, Chen XR, Chen YB, Cheng HP, Chu XK, Chu YP, Cronin-Hennessy D, Dai HL, Dai JP, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, Ding WM, Ding Y, Dong LY, Dong MY, Du SX, Fang J, Fang SS, Fava L, Feng CQ, Friedel P, Fu CD, Fu JL, Fuks O, Gao Y, Geng C, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo T, Guo YP, Han YL, Harris FA, He KL, He M, He ZY, Held T, Heng YK, Hou ZL, Hu C, Hu HM, Hu JF, Hu T, Huang GM, Huang GS, Huang JS, Huang L, Huang XT, Huang Y, Hussain T, Ji CS, Ji Q, Ji QP, Ji XB, Ji XL, Jiang LL, Jiang XS, Jiao JB, Jiao Z, Jin DP, Jin S, Jing FF, Kalantar-Nayestanaki N, Kavatsyuk M, Kloss B, Kopf B, Kornicer M, Kuehn W, Lai W, Lange JS, Lara M, Larin P, Leyhe M, Li CH, Li C, Li C, Li DL, Li DM, Li F, Li G, Li HB, Li JC, Li K, Li L, Li N, Li PR, Li QJ, Li WD, Li WG, Li XL, Li XN, Li XQ, Li XR, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Lin DX, Liu BJ, Liu CL, Liu CX, Liu FH, Liu F, Liu F, Liu HB, Liu HH, Liu HM, Liu JP, Liu K, Liu KY, Liu PL, Liu Q, Liu SB, Liu X, Liu YB, Liu ZA, Liu Z, Liu Z, Loehner H, Lou XC, Lu GR, Lu HJ, Lu JG, Lu XR, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Ma FC, Ma HL, Ma QM, Ma S, Ma T, Ma XY, Maas FE, Maggiora M, Malik QA, Mao YJ, Mao ZP, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Moeini H, Morales Morales C, Moriya K, Muchnoi NY, Muramatsu H, Nefedov Y, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Park JW, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Poling R, Prencipe E, Qi M, Qian S, Qiao CF, Qin LQ, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Redmer CF, Ripka M, Rong G, Ruan XD, Sarantsev A, Schumann S, Shan W, Shao M, Shen CP, Shen XY, Sheng HY, Shepherd MR, Song WM, Song XY, Spataro S, Spruck B, Sun GX, Sun JF, Sun SS, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Tapan I, Thorndike EH, Toth D, Ullrich M, Uman I, Varner GS, Wang B, Wang D, Wang DY, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang QJ, Wang SG, Wang XF, Wang XL, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZH, Wang ZY, Wei DH, Wei JB, Weidenkaff P, Wen QG, Wen SP, Werner M, Wiedner U, Wu LH, Wu N, Wu SX, Wu W, Wu Z, Xia LG, Xia YX, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu QJ, Xu QN, Xu XP, Xu ZR, Xue Z, Yan L, Yan WB, Yan WC, Yan YH, Yang HX, Yang Y, Yang YX, Yang YZ, Ye H, Ye M, Ye MH, Yu BX, Yu CX, Yu HW, Yu JS, Yu SP, Yuan CZ, Yuan WL, Yuan Y, Zafar AA, Zallo A, Zang SL, Zeng Y, Zhang BX, Zhang BY, Zhang C, Zhang CB, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang L, Zhang SH, Zhang XJ, Zhang XY, Zhang Y, Zhang YH, Zhang ZP, Zhang ZY, Zhang Z, Zhao G, Zhao JW, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao TC, Zhao XH, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhou L, Zhou X, Zhou XK, Zhou XR, Zhu K, Zhu KJ, Zhu XL, Zhu YC, Zhu YS, Zhu ZA, Zhuang J, Zou BS, Zou JH; BESIII Collaboration. Observation of a charged charmoniumlike structure Zc(4020) and search for the Zc(3900) in e+e--->pi+pi-hc. Phys Rev Lett. 2013 Dec 13;111(24):242001. doi: 10.1103/PhysRevLett.111.242001. Epub 2013 Dec 10.
PubMed 24483645Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke S, Igo RP Jr, Buitendijk GH, Sim X, Weeks DE, Guymer RH, Merriam JE, Francis PJ, Hannum G, Agarwal A, Armbrecht AM, Audo I, Aung T, Barile GR, Benchaboune M, Bird AC, Bishop PN, Branham KE, Brooks M, Brucker AJ, Cade WH, Cain MS, Campochiaro PA, Chan CC, Cheng CY, Chew EY, Chin KA, Chowers I, Clayton DG, Cojocaru R, Conley YP, Cornes BK, Daly MJ, Dhillon B, Edwards AO, Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ, Gieger C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes G, Ioannidis JP, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, N Keilhauer C, Khan JC, Kim IK, Kiyohara Y, Klein BE, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P, Lotery AJ, Meitinger T, Mitchell P, Mohand-Said S, Moore AT, Morgan DJ, Morrison MA, Myers CE, Naj AC, Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C, Park KH, Pauer GJ, Peachey NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp R, Rudolph G, Ryu E, Sahel JA, Schaumberg DA, Scholl HP, Schwartz SG, Scott WK, Shahid H, Sigurdsson H, Silvestri G, Sivakumaran TA, Smith RT, Sobrin L, Souied EH, Stambolian DE, Stefansson H, Sturgill-Short GM, Takahashi A, Tosakulwong N, Truitt BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L, Vingerling JR, Vithana EN, Webster AR, Wichmann HE, Winkler TW, Wong TY, Wright AF, Zelenika D, Zhang M, Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R, Baird PN, Gorin MB, Wang JJ, Klaver CC, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates JR, Swaroop A, Weber BH, Kubo M, Deangelis MM, Leveillard T, Thorsteinsdottir U, Haines JL, Farrer LA, Heid IM, Abecasis GR; AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013 Apr;45(4):433-9, 439e1-2. doi: 10.1038/ng.2578. Epub 2013 Mar 3.
PubMed 23455636
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Single Nucleotide Polymorphism (SNP) in Patients With and Subjects Without Age-Related Macular Degeneration (AMD)
- ClinicalTrials.gov ID
- NCT00058695
- Acronym / sponsor ID
- 030155
- Conditions
- Macular Degeneration
- Keywords
- Macualar Degeneration, AMD, Healthy Volunteer, HV
- Study type
- Observational
- Recruitment status
- Terminated
- Enrolment
- 477 participants (actual)
- Lead sponsor
- National Eye Institute (NEI)US National Institutes of Health
- Study start
- 4 Apr 2003
- Study completion
- 21 Oct 2015
- First posted
- 11 Apr 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine whether certain polymorphisms (small gene variances) predispose people to develop age-related macular degeneration (AMD). This eye condition affects people over 50 years of age and can cause permanent loss of central vision. The study will examine and compare the frequency of polymorphisms in patients with AMD to that of individuals without AMD. This information will help identify genetic risk factors for the AMD and may lead to the development of more effective treatments.
Patients 50 years of age and older with advanced AMD and healthy normal volunteers may be eligible for this study. All participants will provide an eye health history and will have 10 milliliters (2 teaspoons) of blood drawn from an arm vein. The DNA in the blood will be isolated and tested for certain genes that other research indicates are important in aging and age-related diseases. The normal and polymorphic gene sequences will be identified and compared in patients with AMD and control subjects to determine if any of the polymorphisms are related to development of AMD.
In addition, control subjects will have a routine eye examination, including dilation of the pupils for examination of the back of the eye.
...
Detailed description
Age-related macular degeneration (AMD) is the leading cause of irreversible severe central visual loss older than 50 in the world.1 The incidence and progression of all the features of AMD are known to increase significantly with age.2-4 In a recent study, Klein et al. reported that approximately 15.6% of the US population aged 60 years and older in 2005-2008 had signs of AMD.5 In a study in Iceland, the prevalence of early AMD was 12.4% for those aged 66 to 74 years and 36% for those aged 85 years and older.6 Currently in the United States, advanced AMD affects more than 1.75 million people and the number will increase to 2.95 million by the year 2020.7
Epidemiological studies of genome wide association study (GWAS), candidate gene association, and linkage disequilibrium suggest that AMD has a significant genetic component.7-10 Ample evidence supports the hypothesis that variance of genes involved in DNA repair,11-13 oxidative stress14, 15 and inflammation16-20 play a role in aging and age-related diseases. Many studies have documented the association between polymorphisms in complement factors (CF), oxidative stress, apolipoprotein E (ApoE), mitochondria and chaperone proteins genes and AMD.21-23 Single nucleotide polymorphism (SNP) in ApoE, ApoE or C2/BF may protect AMD. On the other hand, SNP in CFH, AMRS2/HTRA-1 or CX3CR1 gene may increase AMD risk.24 In this study, we would like to test whether the variations of biologically plausible genes (or the modifying genes) listed above are differentially distributed in AMD patients and normal populations. To this end, we choose genes that are believed to play a crucial role in the aging process and will analyze the frequency of SNPs specifically within the coding frames of biologically plausible genes responsible for aging and age-related diseases.
Our aim will be to compare the allelic frequencies of candidate genes listed above in cohorts with AMD to the frequency in normal control subjects without AMD. With this study we hope to identify genetic risk factors that could have functional implications for understanding and treating AMD.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Diagnosis of advanced AMD defined by geographic atrophy and/or choroidal neovascularization with drusen of any size in at least one eye.
- Age 50 years or older.
- If sample previously donated in a different study, the patient has given their permission to use their sample (i.e. marked appropriate selection in the informed consent).
- Absence of drusen or no more than 5 drusen less than 63 microns, absence of other diagnostic criteria for AMD.
- Agrees to undergo study examinations.
Key exclusion criteria (2 listed)
- Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD loss such as high myopia, retinal dystrophies, central serous retinopathy, vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases that have been present prior to the age of 50.
- Opacities of the ocular media, limitations of papillary dilation or other problems sufficient to preclude adequate stereo fundus photography. These conditions include occluded pupils due to synechiae, cataracts, vitreous haze and opacities due to ocular diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Frequency of SNP
Time frame: Ongoing
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2018.
- Background: PubMed 19608872Tuo J, Ross RJ, Herzlich AA, Shen D, Ding X, Zhou M, Coon SL, Hussein N, Salem N Jr, Chan CC. A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. Am J Pathol. 2009 Aug;175(2):799-807. doi: 10.2353/ajpath.2009.090089. Epub 2009 Jul 16.
- Background: PubMed 24483645Ablikim M, Achasov MN, Albayrak O, Ambrose DJ, An FF, An Q, Bai JZ, Baldini Ferroli R, Ban Y, Becker J, Bennett JV, Bertani M, Bian JM, Boger E, Bondarenko O, Boyko I, Braun S, Briere RA, Bytev V, Cai H, Cai X, Cakir O, Calcaterra A, Cao GF, Cetin SA, Chang JF, Chelkov G, Chen G, Chen HS, Chen JC, Chen ML, Chen SJ, Chen XR, Chen YB, Cheng HP, Chu XK, Chu YP, Cronin-Hennessy D, Dai HL, Dai JP, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, Ding WM, Ding Y, Dong LY, Dong MY, Du SX, Fang J, Fang SS, Fava L, Feng CQ, Friedel P, Fu CD, Fu JL, Fuks O, Gao Y, Geng C, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo T, Guo YP, Han YL, Harris FA, He KL, He M, He ZY, Held T, Heng YK, Hou ZL, Hu C, Hu HM, Hu JF, Hu T, Huang GM, Huang GS, Huang JS, Huang L, Huang XT, Huang Y, Hussain T, Ji CS, Ji Q, Ji QP, Ji XB, Ji XL, Jiang LL, Jiang XS, Jiao JB, Jiao Z, Jin DP, Jin S, Jing FF, Kalantar-Nayestanaki N, Kavatsyuk M, Kloss B, Kopf B, Kornicer M, Kuehn W, Lai W, Lange JS, Lara M, Larin P, Leyhe M, Li CH, Li C, Li C, Li DL, Li DM, Li F, Li G, Li HB, Li JC, Li K, Li L, Li N, Li PR, Li QJ, Li WD, Li WG, Li XL, Li XN, Li XQ, Li XR, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Lin DX, Liu BJ, Liu CL, Liu CX, Liu FH, Liu F, Liu F, Liu HB, Liu HH, Liu HM, Liu JP, Liu K, Liu KY, Liu PL, Liu Q, Liu SB, Liu X, Liu YB, Liu ZA, Liu Z, Liu Z, Loehner H, Lou XC, Lu GR, Lu HJ, Lu JG, Lu XR, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Ma FC, Ma HL, Ma QM, Ma S, Ma T, Ma XY, Maas FE, Maggiora M, Malik QA, Mao YJ, Mao ZP, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Moeini H, Morales Morales C, Moriya K, Muchnoi NY, Muramatsu H, Nefedov Y, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Park JW, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Poling R, Prencipe E, Qi M, Qian S, Qiao CF, Qin LQ, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Redmer CF, Ripka M, Rong G, Ruan XD, Sarantsev A, Schumann S, Shan W, Shao M, Shen CP, Shen XY, Sheng HY, Shepherd MR, Song WM, Song XY, Spataro S, Spruck B, Sun GX, Sun JF, Sun SS, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Tapan I, Thorndike EH, Toth D, Ullrich M, Uman I, Varner GS, Wang B, Wang D, Wang DY, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang QJ, Wang SG, Wang XF, Wang XL, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZH, Wang ZY, Wei DH, Wei JB, Weidenkaff P, Wen QG, Wen SP, Werner M, Wiedner U, Wu LH, Wu N, Wu SX, Wu W, Wu Z, Xia LG, Xia YX, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu QJ, Xu QN, Xu XP, Xu ZR, Xue Z, Yan L, Yan WB, Yan WC, Yan YH, Yang HX, Yang Y, Yang YX, Yang YZ, Ye H, Ye M, Ye MH, Yu BX, Yu CX, Yu HW, Yu JS, Yu SP, Yuan CZ, Yuan WL, Yuan Y, Zafar AA, Zallo A, Zang SL, Zeng Y, Zhang BX, Zhang BY, Zhang C, Zhang CB, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang L, Zhang SH, Zhang XJ, Zhang XY, Zhang Y, Zhang YH, Zhang ZP, Zhang ZY, Zhang Z, Zhao G, Zhao JW, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao TC, Zhao XH, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhou L, Zhou X, Zhou XK, Zhou XR, Zhu K, Zhu KJ, Zhu XL, Zhu YC, Zhu YS, Zhu ZA, Zhuang J, Zou BS, Zou JH; BESIII Collaboration. Observation of a charged charmoniumlike structure Zc(4020) and search for the Zc(3900) in e+e--->pi+pi-hc. Phys Rev Lett. 2013 Dec 13;111(24):242001. doi: 10.1103/PhysRevLett.111.242001. Epub 2013 Dec 10.
- Background: PubMed 23455636Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke S, Igo RP Jr, Buitendijk GH, Sim X, Weeks DE, Guymer RH, Merriam JE, Francis PJ, Hannum G, Agarwal A, Armbrecht AM, Audo I, Aung T, Barile GR, Benchaboune M, Bird AC, Bishop PN, Branham KE, Brooks M, Brucker AJ, Cade WH, Cain MS, Campochiaro PA, Chan CC, Cheng CY, Chew EY, Chin KA, Chowers I, Clayton DG, Cojocaru R, Conley YP, Cornes BK, Daly MJ, Dhillon B, Edwards AO, Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ, Gieger C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes G, Ioannidis JP, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, N Keilhauer C, Khan JC, Kim IK, Kiyohara Y, Klein BE, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P, Lotery AJ, Meitinger T, Mitchell P, Mohand-Said S, Moore AT, Morgan DJ, Morrison MA, Myers CE, Naj AC, Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C, Park KH, Pauer GJ, Peachey NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp R, Rudolph G, Ryu E, Sahel JA, Schaumberg DA, Scholl HP, Schwartz SG, Scott WK, Shahid H, Sigurdsson H, Silvestri G, Sivakumaran TA, Smith RT, Sobrin L, Souied EH, Stambolian DE, Stefansson H, Sturgill-Short GM, Takahashi A, Tosakulwong N, Truitt BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L, Vingerling JR, Vithana EN, Webster AR, Wichmann HE, Winkler TW, Wong TY, Wright AF, Zelenika D, Zhang M, Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R, Baird PN, Gorin MB, Wang JJ, Klaver CC, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates JR, Swaroop A, Weber BH, Kubo M, Deangelis MM, Leveillard T, Thorsteinsdottir U, Haines JL, Farrer LA, Heid IM, Abecasis GR; AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013 Apr;45(4):433-9, 439e1-2. doi: 10.1038/ng.2578. Epub 2013 Mar 3.
Related trials for Macular Degeneration
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
RecruitingObservational study
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Age-related Macular Degeneration (AMD)
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingObservational study
Retinal Pigment Epithelium Safety Study For Patients In B4711001
Age Related Macular Degeneration
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert B Nussenblatt, M.D. principal investigator
National Eye Institute (NEI)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Macular Degeneration, run by National Eye Institute (NEI) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of SNP (time frame: Ongoing). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00058695, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2018.